Ontology highlight
ABSTRACT: Background/aims
We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosaassociated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage.Methods
From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records.Results
Of the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori -positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response.Conclusions
Eradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.
SUBMITTER: Gong EJ
PROVIDER: S-EPMC5003192 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
Gong Eun Jeong EJ Ahn Ji Yong JY Jung Hwoon-Yong HY Park Hyungchul H Ko Young Bo YB Na Hee Kyong HK Jung Kee Wook KW Kim Do Hoon do H Lee Jeong Hoon JH Choi Kee Don KD Song Ho June HJ Lee Gin Hyug GH Kim Jin-Ho JH
Gut and liver 20160901 5
<h4>Background/aims</h4>We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosaassociated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage.<h4>Methods</h4>From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medica ...[more]